BioMarin Pharmaceutical Inc. (BMRN) is currently Undervalued by 162.66%

BioMarin Pharmaceutical Inc. (BMRN) appears undervalued by approximately 162.66% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Upside (live) 162.66% (from live valuation API)
Confidence (live) 9.5/10 (Very High)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$58.79

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is BioMarin Pharmaceutical Inc. overvalued or undervalued?

Intrinsic value work anchors BioMarin Pharmaceutical Inc. on owner earnings and balance-sheet capacity; the current quote trades below that anchor, which frames the stock as relatively cheap on a fundamentals-first view.

Versus historical valuation bands, BMRN is closer to the lower end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.

Forward market expectations are muted: the price does not require heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.

Key metrics

P/E ratio: 42.2x
Revenue growth (TTM y/y): 7%
Profit margin: 25.0%
Fair value (model): Unlock

Next steps

Frequently asked questions — BMRN

Is BMRN overvalued right now?

A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for BMRN, then validate with fundamentals and peer multiples.

What is BioMarin Pharmaceutical Inc.'s intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether BMRN trades above or below fair value. At $58.79, BioMarin Pharmaceutical Inc. currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is BioMarin Pharmaceutical Inc.'s intrinsic value calculated?

Tickerplace calculates BMRN's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is BMRN undervalued right now?

Based on our 2026 valuation models, BioMarin Pharmaceutical Inc. (BMRN) appears undervalued at $58.79 with about 162.7% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.

Peers for BMRN: open their overvalued / undervalued view.

Instant valuation answer